ombitasvir, paritaprevir, ritonavir and dasabuvir (Oral route)
om-BIT-as-vir, par-i-TA-pre-vir, rit-OH-na-vir, da-SA-bue-vir
Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with ombitasvir/paritaprevir/ritonavir/dasabuvir. HBV reactivation has been reported in hepatitis C virus (HCV)/HBV coinfected patients who were undergoing or had completed treatment with HCV direct acting antivirals and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated .
Commonly used brand name(s)
In the U.S.
- Viekira Pak
Available Dosage Forms:
Uses For ombitasvir, paritaprevir, ritonavir and dasabuvir
Ombitasvir, paritaprevir, ritonavir, and dasabuvir combination is used with or without ribavirin to treat chronic hepatitis C infection, including patients with compensated cirrhosis.
ombitasvir, paritaprevir, ritonavir and dasabuvir is available only with your doctor's prescription.
Before Using ombitasvir, paritaprevir, ritonavir and dasabuvir
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For ombitasvir, paritaprevir, ritonavir and dasabuvir, the following should be considered:
Tell your doctor if you have ever had any unusual or allergic reaction to ombitasvir, paritaprevir, ritonavir and dasabuvir or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Appropriate studies have not been performed on the relationship of age to the effects of Viekira Pak® in the pediatric population. Safety and efficacy have not been established.
Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of Viekira Pak® in the elderly.
There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.
Interactions with Medicines
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking ombitasvir, paritaprevir, ritonavir and dasabuvir, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.
Using ombitasvir, paritaprevir, ritonavir and dasabuvir with any of the following medicines is not recommended. Your doctor may decide not to treat you with this medication or change some of the other medicines you take.
- Ergoloid Mesylates
- Ethinyl Estradiol
- Isavuconazonium Sulfate
- St John's Wort
Using ombitasvir, paritaprevir, ritonavir and dasabuvir with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.
- Ado-Trastuzumab Emtansine
- Aripiprazole Lauroxil
- Arsenic Trioxide
- Conjugated Estrogens
- Dabigatran Etexilate
- Doxorubicin Hydrochloride Liposome
- Folic Acid
- Fusidic Acid
- Irinotecan Liposome
- Morphine Sulfate Liposome
- Vincristine Sulfate Liposome
Using ombitasvir, paritaprevir, ritonavir and dasabuvir with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.
- Estradiol Cypionate
- Estradiol Valerate
- Ethynodiol Diacetate
- Medroxyprogesterone Acetate
- Tenofovir Disoproxil Fumarate
- Valproic Acid
Interactions with Food/Tobacco/Alcohol
Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.
Using ombitasvir, paritaprevir, ritonavir and dasabuvir with any of the following is usually not recommended, but may be unavoidable in some cases. If used together, your doctor may change the dose or how often you use ombitasvir, paritaprevir, ritonavir and dasabuvir, or give you special instructions about the use of food, alcohol, or tobacco.
- Grapefruit Juice
Other Medical Problems
The presence of other medical problems may affect the use of ombitasvir, paritaprevir, ritonavir and dasabuvir. Make sure you tell your doctor if you have any other medical problems, especially:
- Hepatitis B, history of—Use with caution. May cause this condition to become active again.
- HIV infection—Use with caution. May make this condition worse.
- Liver disease, moderate to severe—Should not be used in patients with this condition.
Proper Use of ombitasvir, paritaprevir, ritonavir and dasabuvir
To help clear up your infection completely, Viekira Pak® may or may not be taken together with ribavirin, for the full time of treatment, even if you begin to feel better after a few days. Also, it is important to keep the amount of medicine in your body at a steady level. To help keep the amount constant, Viekira Pak® must be used on a regular schedule.
ombitasvir, paritaprevir, ritonavir and dasabuvir should come with a Medication Guide. Read and follow the instructions carefully. Ask your doctor if you have any questions.
Viekira Pak® contains 2 different types of tablets: the pink tablet (contains a fixed dose combination of ombitasvir, paritaprevir, ritonavir) and the beige tablet (contains dasabuvir). These tablets should be taken with or without ribavirin, as prescribed by your doctor.
Take ombitasvir, paritaprevir, ritonavir and dasabuvir with food.
The dose of ombitasvir, paritaprevir, ritonavir and dasabuvir will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of ombitasvir, paritaprevir, ritonavir and dasabuvir. If your dose is different, do not change it unless your doctor tells you to do so.
The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.
- For oral dosage form (tablets):
- For chronic hepatitis C virus infection, with or without ribavirin:
- Adults—2 pink tablets once a day (taken in the morning) and 1 beige tablet two times a day (one tablet in the morning and one tablet in the evening).
- Children—Use and dose must be determined by your doctor.
- For chronic hepatitis C virus infection, with or without ribavirin:
If you miss a dose of ombitasvir, paritaprevir, ritonavir and dasabuvir, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.
If it is less than 12 hours from the time your dose was scheduled, take the pink tablet as soon as you can. If you miss a dose and it is more than 12 hours from the time your dose was scheduled, skip the missed dose and take your next dose at the regular time.
If it is less than 6 hours from the time your dose was scheduled, take the beige tablet as soon as you can. If you miss a dose and it is more than 6 hours from the time your dose was scheduled, skip the missed dose and take your next dose at the regular time.
Do not take extra medicine to make up for a missed dose. Call your doctor if you have questions.
Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.
Keep out of the reach of children.
Do not keep outdated medicine or medicine no longer needed.
Ask your healthcare professional how you should dispose of any medicine you do not use.
Precautions While Using ombitasvir, paritaprevir, ritonavir and dasabuvir
It is very important that your doctor check your progress at regular visits to make sure ombitasvir, paritaprevir, ritonavir and dasabuvir is working properly. Blood tests may be needed to check for unwanted effects.
Using ombitasvir, paritaprevir, ritonavir and dasabuvir together with ribavirin while you are pregnant can harm your unborn baby. These medicines may also cause birth defects if the father is using it when his sexual partner becomes pregnant. Avoid pregnancy during combination treatment with ombitasvir, paritaprevir, ritonavir and dasabuvir and ribavirin for 6 months of stopping treatment. If a pregnancy occurs while you are using these medicines, tell your doctor right away.
Do not use the following medicines while you are using ombitasvir, paritaprevir, ritonavir and dasabuvir: alfuzosin (Uroxatral®), cisapride (Propulsid®), colchicine (Colcrys®), dronedarone (Multaq®), efavirenz (Sustiva®), ethinyl estradiol (Norinyl®, Ortho Evra®), everolimus (Afinitor®), gemfibrozil (Lopid®), lurasidone (Latuda®), oral midazolam (Versed®), pimozide (Orap®), ranolazine (Ranexa®), rifampin (Rifadin®, Rimactane®), sildenafil (Revatio®), sirolimus (Rapamune®), St. John's wort, tacrolimus (Prograf®), triazolam (Halcion®), certain medicines to lower cholesterol (such as atorvastatin, lovastatin, simvastatin, Mevacor®, Zocor®), medicine to treat seizures (such as carbamazepine, phenobarbital, phenytoin, Tegretol®), or ergot medicines (such as dihydroergotamine, ergonovine, ergotamine, methylergonovine, Cafergot®, Ergomar®, Wigraine®). Using Viekira Pak® with any of these medicines can cause very serious medical problems.
Check with your doctor right away if you are weak or tired, have onset of confusion, have pain or tenderness in the upper stomach, pale stools, dark urine, loss of appetite, nausea, vomiting, or yellow eyes or skin. These could be symptoms of a serious liver problem.
Do not take other medicines unless they have been discussed with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines and herbal or vitamin supplements.
ombitasvir, paritaprevir, ritonavir and dasabuvir Side Effects
Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur:Less common
- Abdominal or stomach pain
- bloating of the abdomen or stomach
- dark urine
- light-colored stools
- nausea and vomiting
- yellow eyes or skin
- Blistering, peeling, or loosening of the skin
- joint or muscle pain
- red skin lesions, often with a purple center
- red, irritated eyes
- sore throat
- sores, ulcers, or white spots in the mouth or on the lips
- unusual tiredness or weakness
Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:More common
- Itching skin or rash
- lack or loss of strength
- trouble sleeping
Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
See also: Side effects (in more detail)
The information contained in the Truven Health Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.
The use of the Truven Health products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Truven Health and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, TRUVEN HEALTH MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Truven Health does not assume any responsibility or risk for your use of the Truven Health products.
Copyright 2017 Truven Health Analytics, Inc. All Rights Reserved.
More about dasabuvir/ombitasvir/paritaprevir/ritonavir
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Support Group
- En Español
- 9 Reviews – Add your own review/rating
- Drug class: antiviral combinations
- Dasabuvir, ombitasvir, paritaprevir, and ritonavir
- Dasabuvir, ombitasvir, paritaprevir, and ritonavir (Advanced Reading)
- Ombitasvir, Paritaprevir, and Ritonavir with Dasabuvir Sodium (AHFS Monograph)
- Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir (Wolters Kluwer)